Prospective registry of heart failure with preserved ejection fraction in México: EDIFICE-Mx
We observed a substantial comorbidity burden impacting quality of life, as indicated by KCCQ scores. There was a high incidence of hard endpoints, including cardiovascular death and hospitalizations, alongside significant variability in treatment utilization. Future research should focus on elucidating individual healthcare trajectories in HFpEF patients and promoting wider adoption of evidence-based therapies.
Authors
- Ximena Latapi Ruiz Esparza (ORCID: https://orcid.org/0000-0001-6581-8805)
- Rodrigo Gopar‐Nieto (ORCID: https://orcid.org/0000-0002-4865-4869)
- Héctor González‐Pacheco (ORCID: https://orcid.org/0000-0002-4370-9963)
- Diego Araiza‐Garaygordobil (ORCID: https://orcid.org/0000-0003-3185-0051)
- Antonio Jordán‐Ríos (ORCID: https://orcid.org/0000-0001-5972-5709)
- Daniel Martínez (ORCID: https://orcid.org/0000-0003-0308-6973)
- Amada Álvarez‐Sangabriel (ORCID: https://orcid.org/0000-0003-0593-2571)
- Alexandra Arias‐Mendoza (ORCID: https://orcid.org/0000-0002-5942-4102)
- Oscar-Ulises Preciado-Gutierrez
- Sarai Hernandez-Pastrana (ORCID: https://orcid.org/0009-0001-1809-5007)
- B A Diaz-Herrera
Institutions
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1016/j.ahjo.2024.100486
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Novartis
- Novo Nordisk
- Servier
- H. Lundbeck A/S